Highlights
• GlaxoSmithKline (GSK) Australia extends its services agreement with MedAdvisor for a further 12 months
• GSK will continue utilising MedAdvisor’s medication management platform to to provide relevant information for patients prescribed three medicines within GSK Australia’s respiratory portfolio.
• Agreement will generate Patient Engagement Program (PEP), formerly known as Medication Training and Adherence Campaigns (MTAC), revenue for MedAdvisor.
• Allows GSK Australia to leverage the MedAdvisor platform to support patients on the safe and effective use of these medicines.
- Forums
- ASX - By Stock
- Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX
MDR
medadvisor limited
Add to My Watchlist
0.00%
!
8.0¢

Highlights • GlaxoSmithKline (GSK) Australia extends its...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.98M |
Open | High | Low | Value | Volume |
8.0¢ | 8.1¢ | 8.0¢ | $39.78K | 497.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 370000 | 7.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.8¢ | 75865 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 370000 | 0.077 |
2 | 72644 | 0.076 |
1 | 46500 | 0.075 |
2 | 100013 | 0.074 |
1 | 200000 | 0.073 |
Price($) | Vol. | No. |
---|---|---|
0.088 | 75865 | 2 |
0.090 | 40000 | 1 |
0.091 | 100000 | 1 |
0.095 | 10588 | 1 |
0.099 | 26569 | 1 |
Last trade - 15.11pm 20/06/2025 (20 minute delay) ? |
Featured News
MDR (ASX) Chart |